All News
MTX withdrawal in tofacitinib MR 11mg ORAL shift 1y study @week 24, MTX blindly withdrawal for pt achieved LDA (CDAI <=10) n>200 each arm no difference between arms consistent with anecdotal evidence of how pt can withdraw MTX in real life. #eular2019 @RheumNow
Alberta Hoi tuna0sashimi ( View Tweet)
Vagal nerve stimulation for management of RA. Effective in refractory RA #EULAR2019 https://t.co/petEUKty7v
Dr. Dinesh Khanna sclerodermaUM ( View Tweet)
Please please publish this so we can quote it for our patients RT @CreakyJoints: Reassuring news about hair loss and methotrexate: a #EULAR2019 study of around 100 #RA patients found there was minimal hair loss related to MTX therapy. https://t.co/vHis3KZhbz
Alberta Hoi tuna0sashimi ( View Tweet)
#eular2019 H2H abatacept vs adalimumab prev study “AMPLE” showed similar efficacy (single blinded RA <2y study). Now “Early AMPLE” study for seropositive RA with or without HLA shared epitope confirmed previous observation of superiority of ABA at 24w
Alberta Hoi tuna0sashimi ( View Tweet)
It is always an absolute privilege working with Iain
Looking forward to his stint as @eular_org President...his track record suggests there will be some innovations ahead!
@Racegbn @iiiglasgow @UofGMVLS @imidbio https://t.co/932Iz9kayV
Stefan Siebert StefanSiebert1 ( View Tweet)
EULAR HIGHLIGHTS. Ixekizumab beats adalimumab in PsA on combined end pt of skin + joints due to high skin response #EULAR2019 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
EULAR Highlights. 2 new JAKs presented more RA data. Upadacitinib and Filgotinib. Safety of JAKs in meta-analysis -no new safety signals. Tofacitinib use in Corrona = TNFI except slightly more shingles. 7yr Baricitinib data good - no VTE in LTE #EULAR2019 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Eular highlights. RA guidelines still mostly like before - all MOA drugs ok after MTX and still taper if sustained remission. I think don't fully D/C all background Rx in most #EULAR2019 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Eular highlights. Don't forget aerobic supervised exercise to be prescribed in Axial SpA #EULAR2019 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Comparison of high and low iris acid levels in a large cohort of gout patients shows high SUA associated with more comorbidities and CKD, more colchicine & indocin use. #EULAR2019 SAT0435 https://t.co/FvUU4Q6Ky9
Dr. John Cush RheumNow ( View Tweet)
Dr. Peter Lipsky - 1 Million #Gout Patients & who cares for them. SAT0435 #EULAR2018 https://t.co/WfFR4tRf2p
Links:
Dr. John Cush RheumNow ( View Tweet)
A very productive Mentor Mentee meeting with the best mentors and best mentees @EMEUNET #EULAR19 #Madrid https://t.co/nLQkdnK0u3
EMEUNET EMEUNET ( View Tweet)
@drdavidliew @OrphaLung @TobyMMaher @RheumNow See @RheumILD! We love Ritux!
Isabelle Amigues, MD, MS, RhMSUS, human, mom etc isa75012 ( View Tweet)
Eular highlights? SSc trials near misses for efficacy. Abatacept v placebo in early diffuse scleroderma had begun primary outcome for skin but positive composite measure of response (CRISS) TCZ beg on skin but nearly significant; maybe less lung progression #EULAR2019 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Eular highlights SLE Rx Belimumab in largest SLE RCT is safe. Ustikinumab decreases interferon in SLE- Eploratory results from + RCT. Maybe blood levels of hydroxychloroquine may reduce Retinopathy by decreasing dose if high and detect adherence if too low #EULAR2019 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Eular highlights in scleroderma. Nintedanib + for SSc ILD. Positive correlations of combined response in SSc measure and PROs in RCT exploratory analysis of Lenabusum a cannabinoid receptor agonist, maybe riociguat helps Raynauds and digital ulcers #EULAR2019 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Eular highlights Sjögren's syndrome. Maybe new Rx pathway of small early phase RCT with RSLV-132 via toll like receptor 8 acting on interferon - reducing fatigue. Too early to know. #EULAR2019 @RheumNow
Janet Pope Janetbirdope ( View Tweet)
Benefits of #physicalactivity in #rheumatoidarthritis
➡️Disease related outcomes
➡️Systemic outcomes
➡️Financial costs
via @NoreleeK #EULAR2019
#Exercise #arthritis https://t.co/5vnKaPdAQB
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)
Here's a 2 min snapshot of #physicalactivity uptake at #EULAR2019
➡️88% (23) used #escalator
➡️12% (3) used #stairs
➡️87% (20) on escalator stood still
➡️13% (3) walked on escalator
Well done all who used stairs!👍🏽
Good use of facilities & opportunities
https://t.co/7NgdOBtc1z
Dr Ai Lyn Tan DrAiLynTan ( View Tweet)